JP4993301B2 - 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン - Google Patents

日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン Download PDF

Info

Publication number
JP4993301B2
JP4993301B2 JP2007537962A JP2007537962A JP4993301B2 JP 4993301 B2 JP4993301 B2 JP 4993301B2 JP 2007537962 A JP2007537962 A JP 2007537962A JP 2007537962 A JP2007537962 A JP 2007537962A JP 4993301 B2 JP4993301 B2 JP 4993301B2
Authority
JP
Japan
Prior art keywords
virus
mutation
flavivirus
chimeric flavivirus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007537962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520187A5 (cg-RX-API-DMAC7.html
JP2008520187A (ja
Inventor
ファーシャド ギラクー
ジアン リウ
ジョン エー． カタラン
トーマス ピー． モナス
コンスタンティン ブイ． プガチェフ
Original Assignee
サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー filed Critical サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー
Publication of JP2008520187A publication Critical patent/JP2008520187A/ja
Publication of JP2008520187A5 publication Critical patent/JP2008520187A5/ja
Application granted granted Critical
Publication of JP4993301B2 publication Critical patent/JP4993301B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2007537962A 2004-10-20 2005-10-19 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン Expired - Lifetime JP4993301B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US62046604P 2004-10-20 2004-10-20
US60/620,466 2004-10-20
US62094804P 2004-10-21 2004-10-21
US60/620,948 2004-10-21
US67441505P 2005-04-24 2005-04-24
US60/674,415 2005-04-24
US67454605P 2005-04-25 2005-04-25
US60/674,546 2005-04-25
US71892305P 2005-09-19 2005-09-19
US60/718,923 2005-09-19
PCT/US2005/037369 WO2006044857A2 (en) 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus

Publications (3)

Publication Number Publication Date
JP2008520187A JP2008520187A (ja) 2008-06-19
JP2008520187A5 JP2008520187A5 (cg-RX-API-DMAC7.html) 2011-02-03
JP4993301B2 true JP4993301B2 (ja) 2012-08-08

Family

ID=36203650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537962A Expired - Lifetime JP4993301B2 (ja) 2004-10-20 2005-10-19 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン

Country Status (13)

Country Link
US (2) US8029802B2 (cg-RX-API-DMAC7.html)
EP (1) EP1809325B1 (cg-RX-API-DMAC7.html)
JP (1) JP4993301B2 (cg-RX-API-DMAC7.html)
KR (1) KR101501162B1 (cg-RX-API-DMAC7.html)
AU (1) AU2005295438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2584228C (cg-RX-API-DMAC7.html)
EA (1) EA015907B1 (cg-RX-API-DMAC7.html)
IL (1) IL182453A0 (cg-RX-API-DMAC7.html)
MY (1) MY148075A (cg-RX-API-DMAC7.html)
NO (1) NO20071924L (cg-RX-API-DMAC7.html)
NZ (1) NZ584079A (cg-RX-API-DMAC7.html)
SG (1) SG156666A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006044857A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
AU2003267937C1 (en) 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
EP2086581B1 (en) 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
SG2013057732A (en) 2008-08-08 2015-02-27 Ligocyte Pharmaceuticals Inc Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
CA3001374A1 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MX343172B (es) 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
CA3150404A1 (en) 2009-07-31 2011-02-03 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
US10081795B2 (en) * 2010-03-24 2018-09-25 Research Development Foundation Flavivirus host range mutations and uses thereof
CN101926989A (zh) * 2010-06-29 2010-12-29 西北农林科技大学 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
WO2012003320A2 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
EA202090699A3 (ru) 2011-07-11 2020-11-30 Такеда Вэксинс, Инк. Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
AU2014302282B2 (en) 2013-06-26 2018-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines
WO2016079560A1 (en) 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EA035921B1 (ru) * 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
WO2020194063A1 (en) * 2019-03-28 2020-10-01 Institut Pasteur A live and attenuated flavivirus comprising a mutated m protein
WO2024254552A1 (en) * 2023-06-08 2024-12-12 Modernatx, Inc. Stabilized flavivirus vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
NZ337522A (en) * 1997-02-28 2001-02-23 St Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses
US6589533B1 (en) 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
AU9794198A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric vaccine against tick-borne encephalitis virus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2002081753A1 (en) 2001-04-04 2002-10-17 Advanced Research & Technology Institute Method for identifying and characterizing individual dna molecules
WO2003060088A2 (en) 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003267937C1 (en) * 2002-01-15 2019-08-08 Sanofi Pasteur Biologics, Llc Flavivirus vaccines
JP4683926B2 (ja) * 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus

Also Published As

Publication number Publication date
NO20071924L (no) 2007-07-17
MY148075A (en) 2013-02-28
WO2006044857A3 (en) 2006-08-10
EP1809325B1 (en) 2013-11-20
EP1809325A2 (en) 2007-07-25
US8029802B2 (en) 2011-10-04
EA015907B1 (ru) 2011-12-30
EA200700904A1 (ru) 2007-12-28
US8691550B2 (en) 2014-04-08
EP1809325A4 (en) 2009-07-22
CA2584228C (en) 2015-05-05
KR101501162B1 (ko) 2015-03-16
HK1106723A1 (en) 2008-03-20
AU2005295438A1 (en) 2006-04-27
AU2005295438B2 (en) 2012-07-05
US20120201852A1 (en) 2012-08-09
IL182453A0 (en) 2007-07-24
US20070269458A1 (en) 2007-11-22
CA2584228A1 (en) 2006-04-27
KR20070072597A (ko) 2007-07-04
WO2006044857A2 (en) 2006-04-27
NZ584079A (en) 2011-10-28
SG156666A1 (en) 2009-11-26
JP2008520187A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
JP4993301B2 (ja) 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
US8871222B2 (en) Recombinant Flavivirus vaccines
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
US6962708B1 (en) Chimeric flavivirus vaccines
US20130095136A1 (en) Tetravalent Dengue Vaccines
CA2432370C (en) Attenuated flaviviral live vaccine comprising a capsid protein deletion
AU6443198A (en) Chimeric flavivirus vaccines
JP2016501015A (ja) デングウイルス血清型４構築物に関する組成物、方法および使用
IL202978A (en) Arabian Nile Virus vaccine
CN101084010B (zh) 抗日本脑炎病毒及西尼罗病毒的疫苗
AU2013204985B2 (en) Recombinant flavivirus vaccines
HK1106723B (en) Vaccines against japanese encephalitis virus and west nile virus
HK1120431A (en) Recombinant flavivirus vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120402

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120426

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150518

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4993301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250